CFDE Data Portal | Search LINC02009

	Label	Description
	LINC02009 Gene (Entity type)	ENSG00000283646 - long intergenic non-protein coding RNA 2009
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 6 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236228 penfluridol 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 9 v 14 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

LINC02009

ENSG00000283646 - long intergenic non-protein coding RNA 2009

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 13 human up

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 2 human up

A Gene Set from LINCS

GSE77108 saha 0 v 1 human dn

A Gene Set from LINCS

GSE108464 AZ-628 6 v 10 human up

A Gene Set from LINCS

GSE236228 penfluridol 0 v 1 human up

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 9 v 14 human dn

A Gene Set from LINCS

GSE239844 crizotinib 7 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.